DR. JOSEPH LOUIS KENNEDY, M.D.
Medical Practice at Warren Ave, Boston, MA

2014000, Jan 2, 2014

Jun 14, 2013

13/918110

Michael P. Clark - Concord MA, US
Ioana Davies - Watertown MA, US
Huai Gao - Arlington MA, US
Joseph M. Kennedy - Charlestown MA, US
Mark W. Ledeboer - Acton MA, US
Francois Maltais - Tewksbury MA, US
Emanuele Perola - Brookline MA, US

Vertex Pharmaceuticals Incorporated - Cambridge MA

C07D 471/04

514242, 546119, 435238, 514303, 544405, 51425505, 544182

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

2012017, Jul 5, 2012

Dec 15, 2011

13/327206

Paul S. Charifson - Framingham MA, US
Michael P. Clark - Concord MA, US
Upul K. Bandarage - Lexington MA, US
Randy S. Bethiel - Lexington MA, US
John J. Court - Littleton MA, US
Hongbo Deng - Southborough MA, US
Ioana Davies - Watertown MA, US
John P. Duffy - Northborough MA, US
Luc J. Farmer - Montreal, CA
Huai Gao - Arlington MA, US
Wenxin Gu - Concord MA, US
Dylan H. Jacobs - Everett MA, US
Joseph M. Kennedy - Charlestown MA, US
Mark W. Ledeboer - Acton MA, US
Brian Ledford - Norton MA, US
Francois Maltais - Tewksbury MA, US
Emanuele Perola - Brookline MA, US
Tiansheng Wang - Concord MA, US
M. Woods Wannamaker - Bolton MA, US
Randal Byrn - Wayland MA, US
Yi Zhou - Lexington MA, US
Chao Lin - Winchester MA, US
Min Jiang - Lexington MA, US
Steven Jones - Hyde Park MA, US
Ursula A. Germann - Newton MA, US

VERTEX PHARMACEUTICALS INCORPORATED - Cambridge MA

A61K 39/145, A61K 31/506, A61K 31/5377, A61K 31/551, A61K 31/553, A01P 1/00, A01N 43/90, C07D 491/08, C07D 491/107, A61P 31/16, A61P 37/04, C07D 471/04, A61K 31/55

4242091, 544328, 514256, 544122, 5142345, 51421018, 544327, 544295, 51425218, 540575, 514218, 540544, 51421115, 540524, 51421208, 51421021, 540599, 540488, 51421103, 544230, 51425505, 51421016, 51421706

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

2014000, Jan 2, 2014

Jun 14, 2013

13/918048

Michael P. Clark - Concord MA, US
Upul K. Bandarage - Lexington MA, US
Ioana Davies - Watertown MA, US
John P. Duffy - Northborough MA, US
Huai Gao - Arlington MA, US
Jun Feng - Acton MA, US
Jianglin Liang - Needham MA, US
Joseph M. Kennedy - Charlestown MA, US
Mark W. Ledeboer - Acton MA, US
Brian Ledford - Norton MA, US
Francois Maltais - Tewksbury MA, US
Emanuele Perola - Brookline MA, US

Vertex Pharmaceuticals Incorporated - Cambridge MA

C07D 471/04, A61K 31/506, A61K 45/06, A61K 31/5377

5142342, 544122, 544328, 514275, 544230, 435238

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

2013034, Dec 26, 2013

Jun 14, 2013

13/918115

Michael P. Clark - Concord MA, US
Upul K. Bandarage - Lexington MA, US
Hongbo Deng - Southborough MA, US
Ioana Davies - Watertown MA, US
John P. Duffy - Northborough MA, US
Luc J. Farmer - Montreal, CA
Huai Gao - Arlington MA, US
Wenxin Gu - Concord MA, US
Joseph M. Kennedy - Charlestown MA, US
Mark W. Ledeboer - Acton MA, US
Brian Ledford - Norton MA, US
Francois Maltais - Tewksbury MA, US
Emanuele Perola - Brookline MA, US
Marion W. Wannamaker - Bolton MA, US
Tiansheng Wang - Concord MA, US
Francesco G. Salituro - Marlborough MA, US

C07D 471/04

5142345, 544331, 514275, 544127, 546113, 514300, 544182, 514242, 544212, 514245

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

2014004, Feb 13, 2014

Oct 17, 2013

14/056560

Kevin Michael Cottrell - Cambridge MA, US
Hongbo Deng - Southborough MA, US
John P. Duffy - Northborough MA, US
Huai Gao - Arlington MA, US
Simon Giroux - Cambridge MA, US
Jeremy Green - Waltham MA, US
Katrina Lee Jackson - Cambridge MA, US
Joseph M. Kennedy - Charlestown MA, US
David J. Lauffer - Stow MA, US
Mark Willem Ledeboer - Acton MA, US
Pan Li - Lexington MA, US
John Patrick Maxwell - Hingham MA, US
Mark A. Morris - Somerville MA, US
Albert Charles Pierce - Cambridge MA, US
Nathan D. Waal - Cambridge MA, US
Jinwang Xu - Framingham MA, US

C07D 491/048, C07D 471/04, C07D 401/12, C07D 401/14

51426621, 544328, 514256, 544296, 514274, 544284, 435375

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.